While targeting co-activators and co-repressors offers promising therapeutic avenues, several challenges exist. One major challenge is the specificity of these molecules, as they are involved in multiple cellular processes. Achieving selective inhibition without affecting normal cellular functions is crucial. Additionally, the redundancy and compensatory mechanisms within the co-activator and co-repressor networks can complicate therapeutic strategies.
